Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 16/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14529305 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL5076337 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL5076339 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073319 | 0.90 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL4453513 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL4979182 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL4979191 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL28781069 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14032029 | 0.87 | CCR5 (0.85) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14528994 | 0.87 | CCR5 (0.76) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CCR5 1/4885CHRM2 117/4885CHRM1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.